| *Disseminated On Behalf of Liminatus Pharma, Inc.
(Nasdaq: LIMN) Is A Low Float Profile Considering An Ambitious Treasury Proposal
August 15th Dear Reader,
In today’s biopharmaceutical landscape, certain innovators are working at the intersection of cancer research and financial technology, quietly advancing the next generation of immune-based therapies.
One specific company is exploring new ways to strengthen their scientific mission by diversifying capital strategy, even considering digital asset vehicles and block-chain-driven structures.
While clinical development remains their core focus, these recent moves suggest a vision for more flexible, future-oriented funding— positioning them as a company with fast-growing potential for future disruption.
And with a low float under 12.5Mn shares which means heightened volatility could appear in the blink of an eye, this under-the-radar Nasdaq profile has quietly claimed control of our radar:
*Liminatus Pharma, Inc. (Nasdaq: LIMN)*
Liminatus is a preclinical-stage biopharmaceutical company developing immunotherapies for patients with cancer.
They're advancing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune responses.
And based on several potential catalysts, (Nasdaq: LIMN) has quickly moved up my watchlist. Take a look:
#1. Could A Low Float Create A Volatile Scenario?
#2. Liminatus Considers Game-Changing Move To Position Themselves At The Forefront Of Capital Innovation.
#3. IND Submission For IBA101 (Late 2026).
#4. Phase I First-in-Human Trials (Early 2027).
But more on those in a second...
Liminatus Pharma, Inc. (Nasdaq: LIMN) - Complete Company Overview
Liminatus Pharma, Inc. is a biotechnology company based in La Palma, California, specializing in cancer immunotherapy.
Led by CEO Chris Kim, Liminatus operates as a preclinical-stage company focused on developing innovative therapies that target the CD47 immune checkpoint pathway.
Next-Generation Approach to Cancer Therapy
The company’s lead program centers on IBA101, a second-generation CD47 inhibitor antibody.
Unlike earlier CD47 therapies that produced hazardous blood-related side effects such as anemia and thrombocytopenia, IBA101 was engineered to bypass binding to red blood cells and platelets.
Preclinical primate studies demonstrated no significant issues related to blood safety, even at higher dosages, while effectively promoting the destruction of tumor cells by the immune system.
Traditional CD47 therapies work by blocking the “Don’t Eat Me” signal that helps cancer cells evade immune attack.
IBA101 was specifically designed to minimize harm to healthy blood cells—a key limitation of first-generation treatments.
When combined with other immunotherapies, such as anti-PD-1/PD-L1 agents, IBA101 has shown the potential for complete inhibition and regression of tumors in animal models.
Bold Financial Strategy Under Consideration
An ambitious treasury proposal is under review: creation of a $500Mn digital asset in-vest-ment arm.
The intent is to raise funds through private placements, convertible instruments, and equity lines, aiming to support pipeline development while limiting shareholder dilution.
If implemented, this nontraditional fundraising strategy may become a true game-changer.
Exposure to Significant Market Opp's
Liminatus Pharma believs it is well-positioned at the intersection of two rapidly-evolving sectors.
#1. Cancer Immunotherapy / CD47 Therapies
- Market projected to grow to roughly $106.7Bn by 2032.
- Big pharma precedent: $1–$4.9Bn buyouts and licensing deals from Pfizer, AbbVie, and others.
#2. Artificial Blood / Oxygen Carriers
- Market expected to grow to approximately $15.4Bn by 2027.
- Broader human blood products market: approx. $54B by 2031.
- Applications in trauma care, military operations, space exploration, and disaster relief.
Key Advantages Driving Interest
- A CD47 antibody built to tackle earlier safety concerns.
- Potential to benefit from two expanding heal.thcare segments.
- Innovative funding proposal to protect shareholder value.
- A sector track record for major industry buyouts and partnerships.
- Upcoming milestones—including trial initiations and possible licensing deals—could serve as catalysts.
Critical Takeaways
Liminatus Pharma, Inc. is blending scientific innovation with a capital approach that seeks to advance drug development. Clinical milestones and strategic announcements could start drawing significant buzz. Market participants closely monitoring the biotechnology sector may want to investigate Liminatus Pharma for its novel immune-oncology research and unique business model. -----
Based on these 4 potential catalysts, (Nasdaq: LIMN) has taken control of my watchlist. Check them out:
#1. LIMN Potential Catalyst - Could A Low Float Create A Volatile Scenario?
According to info from the MarketWatch website, LIMN has a very low float.
The website reports this profile to have roughly 12.5Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears in the midway part of 2025, could this low float potential help provide a breakout spark? -----
#2. LIMN Potential Catalyst - Liminatus Considers Game-Changing Move To Position Themselves At The Forefront Of Capital Innovation.
Liminatus Pharma Inc. Evaluates Formation of Digital Asset In-vest-ment Vehicle Targeting Up To $500Mn in Capital Strategies
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed
LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset in-vest-ment vehicle.
This initiative marks a bold step toward positioning the Company at the forefront of capital innovation, as it evaluates options to diversify its long-term treasury strategy. The prospective subsidiary—which has not yet been formed and remains under active consideration—would operate independently of Liminatus’s core clinical pipeline and focus on digital asset allocation and block-chain-integrated financial structures.
If approved and executed, the Company anticipates targeting up to $500Mn in potential capital formation through a combination of private placements, convertible instruments, equity line and other structured financing tools. All fundraising activities, if undertaken, would be conducted in full alignment with applicable SEC regulations and exemptions.
...
Read the full article here. -----
#3. LIMN Potential Catalyst - IND Submission For IBA101 (Late 2026).
Liminatus is preparing to transition its work into human trials. The company has finished all required safety and efficacy studies in non-human primates, carried out under GLP conditions at Charles River Laboratories to support regulatory submissions.
Based on these results, it intends to file Investigational New Drug (IND) applications with both the U.S. FDA and Korea’s Ministry of Food and Drug Safety (MFDS) during the second half of 2026.
Approval of these submissions would allow the company to begin clinical testing in humans, creating a path toward potentially significant findings.
#4. LIMN Potential Catalyst - Phase I First-in-Human Trials (Early 2027).
Liminatus is moving quickly from preclinical research to human studies. As outlined in its June 2025 update, the company has completed all required preclinical work and is preparing to initiate clinical evaluations.
GLP-compliant toxicology and pharmacology studies in primates are now complete, clearing the way for regulatory filings and trial preparation. Site activations and patient enrollment are anticipated to start in early 2027.
The company is working in collaboration with Professor Se-Hoon Lee at Samsung Medical Center in Seoul.
The planned Phase I trial will use a 3+3 dose-escalation design, followed by expansion cohorts and combination treatment arms with PD-1/PD-L1 therapies, to assess safety, establish dosage levels, and explore possible therapeutic interactions. -----
(Nasdaq: LIMN) Recap - 4 Potential Catalysts In Our Crosshairs.
#1. Could A Low Float Create A Volatile Scenario?
#2. Liminatus Considers Game-Changing Move To Position Themselves At The Forefront Of Capital Innovation.
#3. IND Submission For IBA101 (Late 2026).
#4. Phase I First-in-Human Trials (Early 2027). -----
Coverage is officially underway on Liminatus Pharma, Inc. (Nasdaq: LIMN).
When updates pop up, I'll get them out quickly, Talk again soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/14/2025 and ending on 08/15/2025 to publicly disseminate information about (LIMN:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (LIMN:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/limn-hopzb/#details | 
